The FDA said in a statement that it had determined that one of the two approved vaccines, Ixchiq (Valneva SE), which contains a live, weakened version of the chikungunya virus, was responsible for 21 ...

The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...

Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...

HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...